Found 4 results
Biomarkers Are Not Drug Targets, and Why That Distinction Costs the Industry Billions
Why conflating biomarkers with drug targets leads to failed trials and billions lost. A deep dive into causal cell-state pharmacology.
AI as Tool vs AI as Inventor: Why the Distinction Will Decide the Next Decade of Patents
There are two versions of "AI in drug discovery" being marketed right now, and they are not the same thing. The distinction will decide the next decade of patents.
PRISMA 2020 in Practice: Five Things Most Systematic Reviews Still Get Wrong
PRISMA 2020 has been the reference reporting standard for systematic reviews for several years. Most journals require it; most reviewers check the checklist. Yet a striking proportion of published reviews still fall short.
Biomarkers Are Not Drug Targets, and Why That Distinction Costs the Industry Billions
If one assumption has quietly cost pharmaceutical R&D more than any other in the past two decades, it is the conflation of biomarker with drug target. They look similar on a slide. They diverge sharply in clinical trials.